(iv) Metal on metal hip replacement

The use of metal on metal bearings in hip replacement has rapidly gained popularity during the last decade. This is probably due to: (a) the problems associated with wear of traditional bearing couples, (b) the increased numbers of younger patients undergoing hip replacement and (c) the superior theoretical tribiological characteristics. However, following this widespread adoption of the metal on metal prosthesis, there has been an exponential increase in the number of adverse reports detailing reactions to metal debris. This review describes the history, development and current evidence surrounding metal on metal hip replacement.     

Efficacy of an eConsult service to cure hepatitis C in primary care

In 2016, an eConsult service was developed within a safety net health system to expand access to hepatitis C (HCV) treatment in the primary care setting. The eConsult system provides individualized treatment recommendations from specially trained primary care pharmacists and primary care physicians to primary care providers with less experience in the rapidly changing treatment of HCV. Since its launch, this service has had a large impact in expanding care to a largely homeless and low-income urban population within our health system. We now aim to evaluate its efficacy in curing HCV. In this retrospective cohort study, we describe rates of sustained virologic response 12 weeks after treatment completion (SVR12) for those who received primary care-based HCV treatment through the eConsult system with those who were treated in primary care independent of an eConsult from 2017 to 2019. We found there was no significant difference in the proportion of patients who achieved SVR12 between the two groups. Overall, >90% of patients who received treatment achieved SVR12. Approximately 40% of patients treated for HCV received an eConsult, suggesting utility of the eConsult in expanding access and coordinating treatment for patients within our network.     

Role of smooth muscle cells in the initiation and early progression of atherosclerosis

The initiation of atherosclerosis results from complex interactions of circulating factors and various cell types in the vessel wall, including endothelial cells, lymphocytes, monocytes, and smooth muscle cells (SMCs). Recent reviews highlight the role of activated endothelium and inflammatory cell recruitment in the initiation of and progression of early atherosclerosis. Yet, human autopsy studies, in vitro mechanistic studies, and in vivo correlative data suggest an important role for SMCs in the initiation of atherosclerosis. SMCs are the major producers of extracellular matrix within the vessel wall and in response to atherogenic stimuli can modify the type of matrix proteins produced. In turn, the type of matrix present can affect the lipid content of the developing plaque and the proliferative index of the cells that are adherent to it. SMCs are also capable of functions typically attributed to other cell types. Like macrophages, SMCs can express a variety of receptors for lipid uptake and can form foam-like cells, thereby participating in the early accumulation of plaque lipid. Like endothelial cells, SMCs can also express a variety of adhesion molecules such as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 to which monocytes and lymphocytes can adhere and migrate into the vessel wall. In addition, through these adhesion molecules, SMCs can also stabilize these cells against apoptosis, thus contributing to the early cellularity of the lesion. Like many cells within the developing plaque, SMCs also produce many cytokines such as PDGF, transforming growth factor-beta, IFNgamma, and MCP-1, all of which contribute to the initiation and propagation of the inflammatory response to lipid. Recent advances in SMC-specific gene modulation have enhanced our ability to determine the role of SMCs in early atherogenesis.     

The surgical decision in tetralogy of Fallot: weighing risks and benefits with decision analysis

The preferred management of the symptomatic infant less than 2 years of age with tetralogy of Fallot remains unsettled. In this study decision analysis was used to assess the risks and benefits of three courses of action: (1) primary intracardiac repair; (2) palliative operation in infancy and delayed intracardiac repair; and (3) treatment with propranolol in infancy and delayed intracardiac repair. For each action the likelihood was determined of three possible outcomes for the patient: (1) death, (2) poor surgical result, or (3) good surgical result. Each outcome was associated with an estimated life expectancy. The best action was defined as that resulting in the longest life expectancy. With use of previously reported data and those from experience at one institution, a range of probabilities was estimated for death before operation, surgical mortality, success of propranolol treatment and hemodynamic result of operation. The choice of action was affected most by the mortality of primary intracardiac repair and the likelihood of a good hemodynamic result from intracardiac repair. Less important factors were the outcome of a palliative operation and the likelihood of success with propranolol therapy. It was found that in the institution studied if the mortality rate of primary intracardiac repair is 10 percent or less, intracardiac repair should be performed; otherwise propranolol treatment, which allows delay in intracardiac repair, should be selected. Both alternatives are preferable to palliative operation. With decision analysis, the clinician can use probabilities and life expectancy appropriate to a given clinical setting in determining the best management for the infant with tetralogy of Fallot.